DDInter573 DDInter899
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dipyridamole {u} (Compound) binds {v} (Gene) ABCC4
Dipyridamole {u} (Compound) upregulates {v} (Gene) CDK6
Dipyridamole {u} (Compound) palliates {v} (Disease) coronary artery disease
Dipyridamole {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Platelet Aggregation
Dipyridamole {u} (Compound) downregulates {v} (Gene) PPP2R5E
Dipyridamole {u} (Compound) causes {v} (Side Effect) Ventricular extrasystoles
Dipyridamole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Turmeric
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Dipyridamole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ginkgo biloba
Dipyridamole {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Dipyridamole (Compound) binds ABCC4 (Gene)
Dipyridamole (Compound) upregulates CDK6 (Gene)
Dipyridamole (Compound) palliates coronary artery disease (Disease)
Dipyridamole (Compound) is included by Decreased Platelet Aggregation (Pharmacologic Class)
Dipyridamole (Compound) downregulates PPP2R5E (Gene)
Dipyridamole (Compound) causes Ventricular extrasystoles (Side Effect)
Dipyridamole may cause a minor interaction that can limit clinical effects when taken with Turmeric
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Theophylline
Dipyridamole may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Dipyridamole may lead to a major life threatening interaction when taken with Ramucirumab